Search Results (60)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Narkewicz, Michael | Person |
Why?
|
| Cystic fibrosis liver disease in the post-modulator era. | Academic Article |
Why?
|
| Cirrhosis and other liver disease in cystic fibrosis. | Academic Article |
Why?
|
| The Emergence of Elastography for Cystic Fibrosis Liver Disease. | Academic Article |
Why?
|
| Markers of cystic fibrosis-associated liver disease. | Academic Article |
Why?
|
| Cholangiocyte biology and cystic fibrosis liver disease. | Academic Article |
Why?
|
| Genetic modifiers of liver disease in cystic fibrosis. | Academic Article |
Why?
|
| Cystic Fibrosis Liver Disease and Ursodeoxycholic Acid: One Small Step Forward, Miles to Go. | Academic Article |
Why?
|
| Cystic Fibrosis Liver Disease Consortium | Grant |
Why?
|
| Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. | Academic Article |
Why?
|
| Health-related Quality of Life in a Prospective Study of Ultrasound to Detect Cystic Fibrosis-related Liver Disease in Children. | Academic Article |
Why?
|
| Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease. | Academic Article |
Why?
|
| Integrating Clinical Ultrasound Into Screening for Cystic Fibrosis Liver Disease: Approach With Caution and Optimism. | Academic Article |
Why?
|
| Prospective study of quantitative liver MRI in cystic fibrosis: feasibility and comparison to PUSH cohort ultrasound. | Academic Article |
Why?
|
| Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor. | Academic Article |
Why?
|